Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
BTAI
$1.64
$
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Next Earnings
2026-02-25
Beta
0.2
Average Volume
Market Cap
Last Dividend
CIK
0001720893
ISIN
US09075P2048
CUSIP
09075P204
CEO
Vimal D. Mehta
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
37
IPO Date
2018-03-08
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia | Discussion will focus on the high unmet need and the lack of FDA-approved treatment options associated with acute agitation episodes in Alzheimer's dementia Large patient population affected by Alzheimer's agitation, with approximately ~100 million annual episodes 1 KOL Roundtable to be held on Friday, February 27, at 2:00 p.m. EST NEW HAVEN, Conn. | GlobeNewsWire | 2026-02-19 07:00:00 |
| Short Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Increases By 32.6% | BioXcel Therapeutics, Inc. (NASDAQ: BTAI - Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totaling 1,365,977 shares, an increase of 32.6% from the December 31st total of 1,030,339 shares. Approximately 6.5% of the shares of the stock are sold short. Based | Defense World | 2026-02-04 04:35:04 |
| BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting | sNDA submission supports the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI ® Submission timeline supports potential approval of IGALMI ® label expansion as early as year-end 2026 NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI®. | GlobeNewsWire | 2026-01-20 07:00:00 |
| Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights | NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary duties to shareholders. If you currently own BioXcel stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about. | Business Wire | 2026-01-15 12:44:00 |
| BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting | Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn. | GlobeNewsWire | 2026-01-12 07:00:00 |
| BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI® | NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it plans to submit a supplemental New Drug Application (sNDA) this month seeking the U.S. Food and Drug Administration's (FDA) approval of IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia. | GlobeNewsWire | 2026-01-07 07:00:00 |
| BioXcel Therapeutics, Inc. (BTAI) Discussion of Managing Acute Agitation in Schizophrenia and Bipolar Disorders at Home Transcript | BioXcel Therapeutics, Inc. (BTAI) Discussion of Managing Acute Agitation in Schizophrenia and Bipolar Disorders at Home Transcript | Seeking Alpha | 2025-12-11 06:42:48 |
| Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions | Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8 Topics Covered by Drs. | GlobeNewsWire | 2025-12-03 07:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-12 | 2026-02-12 | View Filing |
| SC 13G/A | 2026-02-09 | 2026-02-09 | View Filing |
| 8-K | 2026-02-06 | 2026-02-06 | View Filing |
| 8-K | 2026-01-20 | 2026-01-20 | View Filing |
| 4 | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2026-01-12 | 2026-01-12 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2025-12-15 | 2025-12-15 | View Filing |
| 4 | 2025-12-15 | 2025-12-15 | View Filing |
| 4 | 2025-12-15 | 2025-12-15 | View Filing |
| 4 | 2025-12-15 | 2025-12-15 | View Filing |
| 8-K | 2025-12-15 | 2025-12-15 | View Filing |
| ARS | 2025-11-12 | 2025-11-12 | View Filing |
| DEF 14A | 2025-11-12 | 2025-11-12 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-10 | 2025-11-10 | View Filing |
| 4 | 2025-11-03 | 2025-11-03 | View Filing |
| PRE 14A | 2025-10-31 | 2025-10-31 | View Filing |
| 8-K | 2025-10-30 | 2025-10-30 | View Filing |
| 8-K | 2025-10-14 | 2025-10-14 | View Filing |
| 4 | 2025-10-01 | 2025-10-01 | View Filing |
| SC 13G | 2025-10-01 | 2025-10-01 | View Filing |
| 4 | 2025-09-16 | 2025-09-16 | View Filing |
| 4 | 2025-09-16 | 2025-09-16 | View Filing |
| 4 | 2025-09-16 | 2025-09-16 | View Filing |
| 4 | 2025-09-16 | 2025-09-16 | View Filing |
| 8-K | 2025-09-15 | 2025-09-15 | View Filing |
| 8-K | 2025-09-10 | 2025-09-10 | View Filing |
| 4 | 2025-09-02 | 2025-09-02 | View Filing |
| 8-K | 2025-08-27 | 2025-08-27 | View Filing |
| 424B5 | 2025-08-18 | 2025-08-18 | View Filing |
| 8-K | 2025-08-18 | 2025-08-18 | View Filing |
| 8-K | 2025-08-18 | 2025-08-18 | View Filing |
| 8-K | 2025-08-15 | 2025-08-15 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-08-06 | 2025-08-06 | View Filing |
| 424B5 | 2025-08-06 | 2025-08-06 | View Filing |
| 4 | 2025-08-05 | 2025-08-05 | View Filing |
| 4 | 2025-08-05 | 2025-08-05 | View Filing |
| 4 | 2025-08-05 | 2025-08-05 | View Filing |
| 4 | 2025-08-05 | 2025-08-05 | View Filing |
| 8-K | 2025-08-01 | 2025-08-01 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-22 | 2025-07-22 | View Filing |
| 4 | 2025-07-22 | 2025-07-22 | View Filing |
| 4 | 2025-07-22 | 2025-07-22 | View Filing |
| 4 | 2025-07-22 | 2025-07-22 | View Filing |
| 8-K | 2025-07-21 | 2025-07-21 | View Filing |
| 8-K | 2025-07-15 | 2025-07-15 | View Filing |
| 4 | 2025-06-30 | 2025-06-30 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-02 | 2025-06-02 | View Filing |
| 8-K | 2025-05-27 | 2025-05-27 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| 10-Q | 2025-05-12 | 2025-05-12 | View Filing |
| 8-K | 2025-05-12 | 2025-05-12 | View Filing |
| 4 | 2025-05-01 | 2025-05-01 | View Filing |
| S-8 | 2025-04-04 | 2025-04-04 | View Filing |
| 8-K | 2025-04-03 | 2025-04-03 | View Filing |
| 424B5 | 2025-04-03 | 2025-04-03 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 10-K | 2025-03-28 | 2025-03-28 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-21 | 2025-03-21 | View Filing |
| 8-K | 2025-03-21 | 2025-03-21 | View Filing |
| 4 | 2025-03-17 | 2025-03-17 | View Filing |
| 4 | 2025-03-17 | 2025-03-17 | View Filing |
| 4 | 2025-03-17 | 2025-03-17 | View Filing |
| 4 | 2025-03-17 | 2025-03-17 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 8-K | 2025-03-04 | 2025-03-04 | View Filing |
| 424B5 | 2025-03-04 | 2025-03-04 | View Filing |
| 8-K | 2025-03-03 | 2025-03-03 | View Filing |
| SC 13G | 2025-02-14 | 2025-02-14 | View Filing |
| 8-K | 2025-02-06 | 2025-02-06 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 8-K | 2025-01-29 | 2025-01-29 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Larry Williams PercentR Strategy | 30.00% | 1.01 | 266 | 0.02 | 0.06 | 40.07 |
| Super Trend Strategy | 29.09% | 1 | 982 | 0.01 | 0.04 | 39.17 |
| Williams PercentR Strategy | 28.92% | 1 | 472 | 0.02 | 0.05 | 39 |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxx | xxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxx | xxxxx |